Getie Muluabay, Mekonnen Biset Asrade, Seifu Daniel, Mulugeta Yonas, Tebeje Solomon, Tafere Chernet, Amuamuta Asmare
Department of Biomedical Sciences, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, P.O. Box 79, Ethiopia.
Department of Pharmacy, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, P. O. Box 79, Ethiopia.
BMC Cancer. 2025 Jan 30;25(1):175. doi: 10.1186/s12885-025-13583-5.
Chemotherapy is a well-established therapeutic approach for several malignancies, including breast cancer (BCa). However, the clinical efficacy of this drug is limited by cardiotoxicity. Assessing multiple cardiac biomarkers can help identify patients at risk of adverse outcomes from chemotherapy.
To evaluate changes in serum cardiac and inflammatory biomarker levels following chemotherapy among female patients with BCa attending at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.
An experimental study design was used. Forty patients with breast cancer were selected using a convenience sampling method. After obtaining informed consent, 40 paired samples (40 samples before chemotherapy and 40 matched samples after three cycles of chemotherapy) were collected between May 2018 and March 2019. An Elecsys 2010 Troponin-T immunoassay analyzer was used to measure serum levels of cardiac troponin T (cTnT), creatinine kinase-myocardial band (CK-MB), C-reactive protein (CRP), and R and D systemic luminex performance assays were used to measure serum Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF- α). Data were analyzed using the SPSS version 23 package, and a p-value < 0.05 was considered statistically significant.
Among female patients with BCa receiving chemotherapy, 20%, 15%, and 35% of patients had elevated cTnT, CK-MB, and CRP levels, respectively, after three cycles of chemotherapy. In contrast, 15% of patients had baseline elevated CRP levels compared with their respective cutoff values. The mean serum cTnT, CK-MB, CRP, and TNF-α levels significantly increased (p < 0.05) compared with their respective baseline values. However, the IL-6 levels at baseline and after chemotherapy were not significantly different.
This study revealed significant increases in cardiac and inflammatory biomarkers following chemotherapy among female patients with breast cancer in the study area. Therefore, cardiac biomarkers and echocardiography findings were used to assess functional abnormalities and treatment outcomes.
化疗是包括乳腺癌（BCa）在内的多种恶性肿瘤的一种成熟治疗方法。然而，这种药物的临床疗效受到心脏毒性的限制。评估多种心脏生物标志物有助于识别有化疗不良后果风险的患者。
评估埃塞俄比亚亚的斯亚贝巴提库尔·安贝萨专科医院的女性乳腺癌患者化疗后血清心脏和炎症生物标志物水平的变化。
采用实验性研究设计。使用便利抽样方法选取40例乳腺癌患者。在获得知情同意后，于2018年5月至2019年3月期间收集40对样本（化疗前40个样本和化疗三个周期后40个匹配样本）。使用Elecsys 2010肌钙蛋白T免疫分析分析仪测量血清心肌肌钙蛋白T（cTnT）、肌酸激酶同工酶（CK-MB）、C反应蛋白（CRP）水平，并使用R和D系统Luminex性能检测法测量血清白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）水平。使用SPSS 23版软件包进行数据分析，p值<0.05被认为具有统计学意义。
在接受化疗的女性乳腺癌患者中，化疗三个周期后分别有20%、15%和35%的患者cTnT、CK-MB和CRP水平升高。相比之下，15%的患者基线CRP水平高于各自的临界值。与各自的基线值相比，血清cTnT、CK-MB、CRP和TNF-α的平均水平显著升高（p<0.05）。然而，基线和化疗后的IL-6水平无显著差异。
本研究表明，研究区域内女性乳腺癌患者化疗后心脏和炎症生物标志物显著增加。因此，心脏生物标志物和超声心动图检查结果被用于评估功能异常和治疗效果。
